E-cadherin Cancer Research Results

E-cadherin, E-cadherin: Click to Expand ⟱
Source: HalifaxProj(restore)
Type:
Also known as Cadherin1 (CDH1)
E-cadherin, is a type of cell adhesion molecule that plays a crucial role in maintaining tissue structure and cell-cell interactions. In the context of cancer, E-cadherin has been found to be a tumor suppressor gene.

E-cadherin is a transmembrane protein that mediates cell-cell adhesion through its extracellular domain, which interacts with other E-cadherin molecules on adjacent cells. This interaction helps to maintain tissue integrity and prevent cancer cells from invading surrounding tissues.

In many types of cancer, including breast, colon, and prostate cancer, E-cadherin expression is often reduced or lost.
cell adhesion molecules spanning four families of 1) Integrins (α2β1, α5/β1, αL/β2); 2) Cadherins (E-cad, P-cad, N-cad); 3) Ig-CAMs (VCAM, NCAM, ICAM, Nectins, Necl); and 4) Selectins (E-selectin, P-selectin, L-selectin).
Scientific Papers found: Click to Expand⟱
6436- T4O,    Terpinen-4-ol suppresses proliferation and motility of cutaneous squamous cell carcinoma cells by enhancing calpain-2 expression
- in-vitro, Melanoma, A431
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, AntiTum↑, cal2↑, cl‑β-catenin/ZEB1↑, cl‑Casp12↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, BAX↑, TumCCA↑, selectivity↑, N-cadherin↓, E-cadherin↑, Ki-67↓, PCNA↑,
1137- Taur,    Taurine Attenuates Epithelial-Mesenchymal Transition-Related Genes in Human Prostate Cancer Cells
- in-vitro, Pca, NA
N-cadherin↓, Twist↓, Zeb1↓, Snail↓, Vim↓, E-cadherin↑,
1138- TQ,    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,
1935- TQ,    Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis
- Review, OS, NA
Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, ROS↑, P53↑, Twist↓, E-cadherin↑, N-cadherin↓, NF-kB↓, IL8↓, XIAP↓, Bcl-2↓, STAT3↓, MAPK↓, PI3K↓, Akt↓, ERK↓, MMP2↓, MMP9↓, *ROS↓, HO-1↑, selectivity↑, TumCG↓,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2/PTGS2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27/CDKN1B↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2/KDR/Flk1↓, Ki-67↓, COX2/PTGS2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
1139- UA,    Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells
- in-vitro, Lung, A549
TumMeta↓, AEG1↓, E-cadherin↑, N-cadherin↓, Vim↓, EMT↓,
5022- UA,    Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↑, TumMeta↓, BioAv↓, Hif1a↓, Glycolysis↓, mitResp↓, Akt↓, MAPK↓, ERK↓, mTOR↓, P53↑, P21↑, E2Fs↑, STAT3↓, MMP↓, NLRP3↓, iNOS↓, CHK1↓, Chk2↓, BRCA1↓, E-cadherin↑, N-cadherin↓, Casp↑, p62↓, LC3II↑, Vim↓, ROS↑, CSCs↓, DNAdam↑, GutMicro↑, VEGF↓,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
1217- VitC,    High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition
- in-vitro, BC, Bcap37 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, Vim↓, EMT↓,
2366- VitD3,    Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells
- in-vitro, BC, MCF7
Glycolysis↓, tumCV↓, Apoptosis↑, mTOR↓, AMPK↑, EMT↓, E-cadherin↑, F-actin↑, Vim↓,
1740- VitD3,    Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms
- Review, Var, NA
Risk↓, eff↑, eff↑, Risk↓, Risk↓, ChemoSen↑, RadioS↑, Cyt‑c↑, Casp3↑, Casp9↑, hTERT/TERT↓, eff↑, E-cadherin↑, CLDN2↑, ZO-1↑, Snail↓, Zeb1↓, Vim↓, VEGF↓, NK cell↑, Risk↓, eff↑,
1821- VitK3,    Menadione (Vitamin K3) induces apoptosis of human oral cancer cells and reduces their metastatic potential by modulating the expression of epithelial to mesenchymal transition markers and inhibiting migration
- in-vitro, Oral, NA - in-vitro, Nor, HEK293 - in-vitro, Nor, HaCaT
selectivity↑, TumCD↓, BAX↑, P53↑, Bcl-2↓, p65↓, E-cadherin↑, EMT↓, Vim↓, Fibronectin↓, TumCG↓, TumCMig↓,
1820- VitK3,    Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1/CCND1↓, TumCCA↑,

Showing Research Papers: 201 to 218 of 218
Prev Page 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 218

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

HO-1↑, 1,   ROS↑, 5,   ROS⇅, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   mitResp↓, 1,   MMP↓, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 3,   GlucoseCon↓, 1,   Glycolysis↓, 3,   HK2↓, 1,   lactateProd↓, 1,   NADPH↓, 1,   PKM2↓, 1,   PPARγ↓, 1,   SIRT1↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 2,   Apoptosis↑, 7,   BAX↑, 6,   Bcl-2↓, 5,   Bcl-2↑, 1,   Bcl-xL↓, 1,   Casp↑, 2,   cl‑Casp12↑, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp7↑, 2,   Casp9↑, 3,   Chk2↓, 1,   Cyt‑c↑, 2,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↓, 2,   p‑MAPK↑, 1,   MDM2↑, 2,   p27/CDKN1B↑, 1,   p38↑, 1,   p‑p38↑, 1,   survivin↓, 2,   TumCD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,   p62↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA1↓, 1,   CHK1↓, 1,   DNAdam↑, 1,   DNMT1↓, 1,   P53↑, 5,   p53 Wildtype↑, 1,   PARP↑, 1,   cl‑PARP↑, 2,   PCNA↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   cycD1/CCND1↓, 5,   E2Fs↑, 1,   P21↑, 2,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   EMT↓, 13,   ERK↓, 4,   ERK↑, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   mTOR↓, 5,   p‑mTOR↓, 1,   p300↓, 1,   PI3K↓, 4,   PTEN↑, 2,   STAT3↓, 3,   p‑STAT3↓, 2,   TOPflash↓, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   cal2↑, 1,   CLDN2↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 17,   F-actin↑, 1,   Fibronectin↓, 1,   Ki-67↓, 2,   MET↓, 1,   MMP2↓, 3,   MMP7↓, 1,   MMP9↓, 4,   MMPs↓, 1,   N-cadherin↓, 11,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 5,   TGF-β↓, 1,   TumCI↓, 5,   TumCMig↓, 7,   TumCP↓, 6,   TumMeta↓, 5,   Twist↓, 5,   Vim↓, 13,   Zeb1↓, 5,   ZO-1↑, 2,   β-catenin/ZEB1↓, 3,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   angioG↑, 2,   Hif1a↓, 2,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   CXCR4↓, 2,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   JAK2↓, 2,   NF-kB↓, 3,   p‑NF-kB↑, 1,   NK cell↑, 1,   p65↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 3,   eff↓, 1,   eff↑, 8,   RadioS↑, 2,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

BRCA1↓, 1,   EZH2↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 2,   NOS2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   Risk↓, 4,  
Total Targets: 146

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 1,   GSTA1↑, 1,   MDA↓, 1,   ROS↓, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

NAD↑, 1,   SIRT1↑, 1,  

Migration(tgid=13) ⓘ

MMP13↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   CRP↓, 1,   IL1β↓, 2,   IL6↓, 1,   Inflam↓, 2,   PGE2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↝, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 1,  
Total Targets: 26

Scientific Paper Hit Count for: E-cadherin, E-cadherin
16 Curcumin
11 Resveratrol
7 Fisetin
7 Luteolin
7 Quercetin
6 Pterostilbene
6 Sulforaphane (mainly Broccoli)
6 Thymoquinone
5 Honokiol
4 Astragalus
4 Cisplatin
4 Apigenin (mainly Parsley)
4 Artemisinin
4 Berberine
4 Chrysin
4 Inositol
4 Piperine
4 Rosmarinic acid
4 Silymarin (Milk Thistle) silibinin
3 Baicalein
3 Propolis -bee glue
3 Cinnamon
3 5-fluorouracil
3 Cyclopamine
3 Eugenol
3 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
3 Magnolol
3 Urolithin
2 Allicin (mainly Garlic)
2 Baicalin
2 Biochanin A
2 Betulinic acid
2 Boron
2 Capsaicin
2 Carvacrol
2 Chlorogenic acid
2 Hydroxycinnamic-acid
2 Citric Acid
2 Ellagic acid
2 Emodin
2 Fucoidan
2 Garcinol
2 Grapeseed extract
2 Hydrogen Gas
2 Isoliquiritigenin
2 Juglone
2 Kaempferol
2 Laetrile B17 Amygdalin
2 Lycopene
2 Piperlongumine
2 Shikonin
2 Selenite (Sodium)
2 Ursolic acid
2 Vitamin D3
2 VitK3,menadione
1 1,8-Cineole
1 3-bromopyruvate
1 Alpha-Lipoic-Acid
1 alpha Linolenic acid
1 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
1 Aspirin
1 Astaxanthin
1 Beta-Caryophyllene
1 Boswellia (frankincense)
1 brusatol
1 Butyrate
1 Caffeic acid
1 Cannabidiol
1 Celecoxib
1 Centella asiatica / Gotu kola → asiaticoside
1 Crocetin
1 Oxaliplatin
1 diet FMD Fasting Mimicking Diet
1 Ginkgo biloba-EGb 761
1 EGCG (Epigallocatechin Gallate)
1 Eurycomanone
1 Evodiamine
1 Ferulic acid
1 Sorafenib (brand name Nexavar)
1 Shilajit/Fulvic Acid
1 Galloflavin
1 Paclitaxel/Taxol
1 Ginkgo biloba
1 Ginkgolide B
1 Proanthocyanidins
1 Chemotherapy
1 HydroxyTyrosol
1 capecitabine
1 Melatonin
1 Metformin
1 Naringin
1 Oroxylin A
1 Oleuropein
1 Phenylbutyrate
1 Phenethyl isothiocyanate
1 Docetaxel
1 Rutin
1 salinomycin
1 Selenate
1 statins
1 Terpinen-4-ol / Tea Tree Oil
1 Taurine
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:89  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page